An essential step in the care of people with gender dysphoria is hormone therapy combining an anti-androgen and estrogen therapy in transgender women (formerly male to female) or androgen therapy in transgender men (female to male). Several studies have shown an increase in cardiovascular risk in these people treated and the European Society of Endocrinology also recommends the monitoring of cardiovascular risk factors in this risky population.~Furthermore, sex steroid hormones as well as gonadotropins have been shown to be associated with the occurrence of ventricular arrhythmias in several animal and human studies. Indeed, from puberty to menopause, the QT is longer in women than in men in the general population. Moreover, it is well established that women are at particular risk of ventricular arrhythmia. Recent publications have also illustrated the shortening of QTc in women in a situation of biological hyperandrogenism and its lengthening in hypogonadal men. These data suggest that sex hormones do play a role in repolarization. Moreover, FSH also appears to be a major determinant positively correlated with the duration of ventricular repolarization. However, the ECG measurement of QT is a simple and non-invasive marker for evaluating this ventricular repolarization.~To date, no study has yet focused on changes in cardiac repolarization in the transgender population treated with hormone therapy.~Therefore, the aim of our study is to evaluate the impact of feminizing and masculinizing hormone treatment on ventricular repolarization in a population of treated transgender people, followed in the Endocrinology department of the Haut-Lévêque hospital in Pessac, compared to the cisgender population.
The consequences of hormonal treatment in transgender patients are still unknown. Thanks to the retrospective collection of control ECG data before and after hormone therapy, the impact of feminizing and masculinizing hormone treatment on ventricular repolarization in a population of treated transgender people, followed in the Endocrinology department of the Haut- Lévêque in Pessac, will be studied and compared with the cisgender population.